Losartan Potassium
Product Images NDC 53002-5624

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 53002-5624). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl530025624)

Packaging label for Losartan Potassium 25 mg tablets by RPK Pharmaceuticals, Inc., displaying dosage instructions to take 1 tablet daily or as directed. The label includes prescription-only designation, tablet description as green oval, and placeholders for clinic name, patient, prescriber, and dispenser information. The package count is 100 tablets.*

FDA Label Image

Figure1 (Losartan Fig1)

A line chart comparing the percentage of patients with a primary endpoint over study months for two drugs: Atenolol (dotted line) and Losartan Potassium (solid line). The graph highlights an adjusted risk reduction of 13% for Losartan Potassium with a p-value of 0.021.*

FDA Label Image

Figure2 (Losartan Fig2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over a 66-month study period for Atenolol (dotted line) and Losartan Potassium (solid line). The graph indicates an adjusted risk reduction of 25% for Losartan Potassium with p=0.001.*

FDA Label Image

Figure 3 (Losartan Fig3)

Figure 3 is a forest plot chart comparing primary endpoint events and stroke events between Losartan Potassium and Atenolol within demographic subgroups. It shows event rates (percent) and hazard ratios with 95% confidence intervals across groups defined by age, gender, race, ischemic heart status, diabetes, and history of cardiovascular disease, displaying favorability trends for both drugs.*

FDA Label Image

Figure-4 (Losartan Fig4)

A line graph depicting cumulative percentage of patients with an event over 48 months. The plot compares Losartan Potassium (solid line) versus placebo (dashed line), with noted risk reduction of 16.1% and a p-value of 0.022.*

FDA Label Image

Chemical Structure (Losartan Str)

Chemical structure of Losartan Potassium, showing the molecular arrangement including the losartan moiety and potassium ion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.